about
Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 casesIn situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral productionCyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERβ) in human prostate cancerGlutamate receptors and the regulation of steroidogenesis in the human adrenal gland: the metabotropic pathwayAromatase expression in atypical ductal hyperplasia in women.3βHSD and CYB5A double positive adrenocortical cells during adrenal development/agingDynorphin knockout reduces fat mass and increases weight loss during fasting in mice.Identification of androgen-responsive microRNAs and androgen-related genes in breast cancer.Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma.Phase two steroid metabolism and its roles in breast and prostate cancer patientsThe mouse as a model to investigate sex steroid metabolism in the normal and pathological prostate.Androgen receptor in triple negative breast cancer.Estrogen receptor expression and its relevant signaling pathway in prostate cancer: a target of therapy.The intracrinology of breast cancer.Complexities of androgen receptor signalling in breast cancer.Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.Beyond the C18 frontier: Androgen and glucocorticoid metabolism in breast cancer tissues: The role of non-typical steroid hormones in breast cancer development and progression.The Role of Androgen Under Normal and Pathological Conditions in Sebaceous Glands: The Possibility of Target Therapy.Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.Possible roles for glucocorticoid signalling in breast cancer.Serotonin receptor 4 (5-hydroxytryptamine receptor Type 4) regulates expression of estrogen receptor beta and cell migration in hormone-naive prostate cancer.Androgen and breast cancer: an update.How far have we come in terms of estrogens in breast cancer? [Review].11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer.Steroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditions.Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.The correlation between body mass index and breast cancer risk or estrogen receptor status in Okinawan women.Clinical significance of subtype classification in metastatic lymph nodes of breast cancer patients undergoing neoadjuvant chemotherapy.Long-term corticosterone treatment induced lobe-specific pathology in mouse prostate.Measurement of sex steroids in murine blood and reproductive tissues by liquid chromatography-tandem mass spectrometry.A patient with POEMS syndrome: the pathology of glomerular microangiopathy.Severe subfertility in mice with androgen receptor inactivation in sex accessory organs but not in testis.Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation.Randomized trial of aromatherapy versus conventional care for breast cancer patients during perioperative periods.The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.Expression of AR, 5αR1 and 5αR2 in bladder urothelial carcinoma and relationship to clinicopathological factors.Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer.Progesterone arrested cell cycle progression through progesterone receptor isoform A in pancreatic neuroendocrine neoplasm.Androgen receptor, androgen-producing enzymes and their transcription factors in extramammary Paget disease.
P50
Q21999477-173A4E4F-F821-40A9-9D36-DEA536B54424Q26825204-DDEAFA99-3A61-4FE7-B3D6-50EEBEBDE619Q28276867-BADA22C9-E57E-4ADD-9E16-FA08907E83E3Q28299516-D8F2353F-0F0B-4081-A838-7C4428DE8E4DQ30252881-8708CAB9-F7E8-46B4-B27A-BE03A7050E53Q34566644-A00C5DE2-1B05-4622-AC86-4E769F5D49E2Q34622489-7355F7D0-CB55-4CC9-94D4-3E10916DE0FCQ35039862-6380D062-D183-467F-9B5A-ACF1B73F402BQ35713540-87DD1981-64A5-41D9-B5B0-733FCA076361Q36903378-FEE9D847-7AD2-4355-B01A-50889EB42CB1Q37142561-EC8CC41A-2A8C-40B9-B180-89021FF0AFC2Q37965350-44C61274-E3A1-43A9-956C-8A2A20066CFEQ38043820-5AE84B18-A783-4C0E-9102-43EB310BB31EQ38072767-92D53594-C956-4FFA-B2AF-252EE05AAE2EQ38206044-DE504016-84D3-4107-AD71-098A7D3EC425Q38222027-6E27AC48-8F8E-4D55-AA81-BD44AEFB21FEQ38399495-973E2CA0-CB95-4E3C-B108-06FEBE515CFCQ38522091-790ACCEB-2080-4FE4-9BA6-238D487A15B6Q38544540-EC829543-1F82-489D-B01D-C8067D05C55FQ38647802-041E012E-8305-4B45-A169-DCF839541362Q38661183-A15E5E5B-5B9F-4918-AC3A-3D1BE453EA91Q38716565-ABCB315D-1270-4431-AD3D-CF726A278B48Q38761566-B6F249FC-0940-4BFE-BA46-7B84CF5054F5Q38791218-D750EC5B-2B4D-46BF-BDCE-CD537A401B5AQ38853492-4980A435-8D19-45AD-8461-3F49AF1D946FQ38968889-4B9BB238-FD1D-4E66-8DE8-94A5B1D1AF71Q39006065-D1C3121C-64FF-41AF-BF84-BD366CACEA73Q39118621-EEDCD1D1-358A-4F79-9B70-80BDC0BD421AQ41582791-2CD4AE0C-221B-49E5-9C97-A85DABD4E254Q42475881-EFB9CD21-483E-4A64-AD40-7AB3313BFB4AQ43166996-7A034D30-0356-4383-B2D4-26EA6E50964CQ45798748-52BCE1B4-916D-404E-AFE7-0E6B776744E2Q45871316-C1B16B6F-1BFC-4D1A-8284-20FB323226B9Q46732371-C75A251E-35D4-463D-8135-D24D6F028D90Q47577157-479737BB-6A4C-4E8B-88D9-99333DFD8E3EQ47631123-EFC7D555-41EB-4C3F-88C2-79B516A6F012Q47745060-5C0C5BD8-BAFD-4B46-9476-C9EC82AE5384Q48376604-E3E3ECAA-03DF-46ED-A14B-CA6F3113B568Q50054658-DC0699DF-93CE-490C-AB6B-82D68D213933Q50437292-085A74BC-040C-40C4-A29F-75145FF334AA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Keely May McNamara
@ast
Keely May McNamara
@en
Keely May McNamara
@es
Keely May McNamara
@nl
Keely May McNamara
@sl
type
label
Keely May McNamara
@ast
Keely May McNamara
@en
Keely May McNamara
@es
Keely May McNamara
@nl
Keely May McNamara
@sl
prefLabel
Keely May McNamara
@ast
Keely May McNamara
@en
Keely May McNamara
@es
Keely May McNamara
@nl
Keely May McNamara
@sl
P106
P31
P496
0000-0002-1982-5737